Sign in6 stories
Annexon says early GBS trial data support a planned BLA filing this quarter, while its geographic atrophy program adds a Month 24 endpoint and a $200 million credit facility extends cash runway into 2028.
SEC filing
The biopharmaceutical company named Blumenkranz a Class II director on August 10, 2026, while longtime director Satter resigned effective immediately before the appointment.
SEC filing
All ten patients receiving tanruprubart showed rapid strength gains within days, and the company still targets a Q4 2026 BLA filing.
SEC filing
The biopharma company drew $50 million at closing, with more available as its two late-stage programs hit certain milestones.
SEC filing